Related Experiment Videos
Experimental meningococcal septicemia. Effect of aspirin therapy
Abstract:
In previous studies we have presented morphological evidence that the terminal shock-like phase of fatal meningococcemia is caused by the occlusion of the pulmonary microcirculation with thrombi composed of platelets, leukocytes, and fibrin. We have also shown that in experimental meningococcemia, pretreatment of rabbits with heparin sodium prevents fibrin formation but does not influence the cellular pulmonary thrombi and does not prolong survival. If our theory is correct, drugs that inhibit platelet aggregation and leukocyte adhesion in rabbits should prolong life. The present experiment demonstrates that pretreatment with a small dose of aspirin doubles the survival time without altering the mortality.
Insights
Aspirin treatment in experimental meningococcemia significantly doubled survival time in rabbits. This suggests that inhibiting platelet aggregation and leukocyte adhesion may be a viable strategy for treating this condition.
Area of Science:
- Medical Microbiology
- Hematology
- Pharmacology
Background:
- Fatal meningococcemia involves pulmonary microcirculation occlusion by platelet, leukocyte, and fibrin thrombi.
- Heparin sodium prevents fibrin but not cellular thrombi, and does not improve survival in experimental meningococcemia.
Purpose of the Study:
- To investigate if inhibiting platelet aggregation and leukocyte adhesion prolongs survival in experimental meningococcemia.
Main Methods:
- Rabbits with experimental meningococcemia were pretreated with a small dose of aspirin.
- Survival time and mortality rates were monitored.
Main Results:
- Aspirin pretreatment doubled the survival time of rabbits.
- Aspirin did not alter the mortality rate.
Conclusions:
- Inhibiting platelet aggregation and leukocyte adhesion with aspirin shows potential for increasing survival in meningococcemia.
- Further research into aspirin's role in managing meningococcemia is warranted.